Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy: predicting the severity of Duchenne muscular dystrophy: implications for treatment.

Kyriakides T, Pegoraro E, Hoffman EP, Piva L, Cagnin S, Lanfranchi G, Griggs RC, Nelson SF.

Neurology. 2011 Nov 15;77(20):1858; author reply 1858-9. doi: 10.1212/WNL.0b013e318239b9ae. No abstract available.

PMID:
22084278
2.

Predicting the severity of Duchenne muscular dystrophy: implications for treatment.

Nelson SF, Griggs RC.

Neurology. 2011 Jan 18;76(3):208-9. doi: 10.1212/WNL.0b013e3182074c0e. Epub 2010 Dec 22. No abstract available.

PMID:
21178098
3.

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, Ermani M, Bello L, Soraru G, Pacchioni B, Bonifati MD, Lanfranchi G, Angelini C, Kesari A, Lee I, Gordish-Dressman H, Devaney JM, McDonald CM; Cooperative International Neuromuscular Research Group.

Neurology. 2011 Jan 18;76(3):219-26. doi: 10.1212/WNL.0b013e318207afeb. Epub 2010 Dec 22.

4.

TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle.

Piva L, Gavassini BF, Bello L, Fanin M, Soraru G, Barp A, Ermani M, Angelini C, Hoffman EP, Pegoraro E.

J Pathol. 2012 Oct;228(2):251-9. doi: 10.1002/path.4026. Epub 2012 Aug 28.

5.

Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.

Bello L, Piva L, Barp A, Taglia A, Picillo E, Vasco G, Pane M, Previtali SC, Torrente Y, Gazzerro E, Motta MC, Grieco GS, Napolitano S, Magri F, D'Amico A, Astrea G, Messina S, Sframeli M, Vita GL, Boffi P, Mongini T, Ferlini A, Gualandi F, Soraru' G, Ermani M, Vita G, Battini R, Bertini E, Comi GP, Berardinelli A, Minetti C, Bruno C, Mercuri E, Politano L, Angelini C, Hoffman EP, Pegoraro E.

Neurology. 2012 Jul 10;79(2):159-62. doi: 10.1212/WNL.0b013e31825f04ea. Epub 2012 Jun 27.

6.

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.

van den Bergen JC, Hiller M, Böhringer S, Vijfhuizen L, Ginjaar HB, Chaouch A, Bushby K, Straub V, Scoto M, Cirak S, Humbertclaude V, Claustres M, Scotton C, Passarelli C, Lochmüller H, Muntoni F, Tuffery-Giraud S, Ferlini A, Aartsma-Rus AM, Verschuuren JJ, 't Hoen PA, Spitali P.

J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1060-5. doi: 10.1136/jnnp-2014-308409. Epub 2014 Dec 4.

7.

Modifier genes and their effect on Duchenne muscular dystrophy.

Vo AH, McNally EM.

Curr Opin Neurol. 2015 Oct;28(5):528-34. doi: 10.1097/WCO.0000000000000240. Review.

PMID:
26263473
8.

[Treatment of Duchenne muscular dystrophy with gentamicin].

Matsuo M, Takeshima Y, Yagi M, Ishibashi K, Wada H.

No To Hattatsu. 2004 Mar;36(2):125-9. Review. Japanese.

PMID:
15031986
9.

PTC124, nonsense mutations and Duchenne muscular dystrophy.

Wilton S.

Neuromuscul Disord. 2007 Oct;17(9-10):719-20. No abstract available.

PMID:
17952895
10.

Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.

Bello L, Kesari A, Gordish-Dressman H, Cnaan A, Morgenroth LP, Punetha J, Duong T, Henricson EK, Pegoraro E, McDonald CM, Hoffman EP; Cooperative International Neuromuscular Research Group Investigators.

Ann Neurol. 2015 Apr;77(4):684-96. doi: 10.1002/ana.24370. Epub 2015 Mar 13.

11.

Duchenne muscular dystrophy improved by gentamicin.

Senior K.

Mol Med Today. 1999 Nov;5(11):461. No abstract available.

PMID:
10529784
12.

Corticosteroids in Duchenne muscular dystrophy: a reappraisal.

Wong BL, Christopher C.

J Child Neurol. 2002 Mar;17(3):183-90. Review.

PMID:
12026233
13.

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR, King WM, Pestronk A, Florence JM, Mathews KD, Finkel RS, Swoboda KJ, Gappmaier E, Howard MT, Day JW, McDonald C, McNally EM, Weiss RB; United Dystrophinopathy Project.

Ann Neurol. 2013 Apr;73(4):481-8. doi: 10.1002/ana.23819. Epub 2013 Feb 20.

14.

[Combination therapy of corticosteroid and gentamicin for Duchenne muscular dystrophy--a basic study].

Kondo E, Kawamichi Y, Sagara Y, Saito K.

No To Hattatsu. 2009 Mar;41(2):132-4. Japanese. No abstract available.

PMID:
19517780
15.

A patient with Duchenne muscular dystrophy and autism demonstrates a hemizygous deletion affecting Dystrophin.

Erturk O, Bilguvar K, Korkmaz B, Bayri Y, Bayrakli F, Arlier Z, Ozturk AK, Yalcinkaya C, Tuysuz B, State MW, Gunel M.

Am J Med Genet A. 2010 Apr;152A(4):1039-42. doi: 10.1002/ajmg.a.33312. No abstract available.

PMID:
20358624
16.

Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy.

Barp A, Bello L, Politano L, Melacini P, Calore C, Polo A, Vianello S, Sorarù G, Semplicini C, Pantic B, Taglia A, Picillo E, Magri F, Gorni K, Messina S, Vita GL, Vita G, Comi GP, Ermani M, Calvo V, Angelini C, Hoffman EP, Pegoraro E.

PLoS One. 2015 Oct 29;10(10):e0141240. doi: 10.1371/journal.pone.0141240. eCollection 2015.

17.

Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy.

Dooley JM, Gordon KE, MacSween JM.

Pediatr Neurol. 2010 Sep;43(3):173-6. doi: 10.1016/j.pediatrneurol.2010.04.013.

PMID:
20691938
18.

Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.

Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF.

Ann Neurol. 2000 Aug;48(2):164-9.

PMID:
10939566
19.

Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.

Platenburg G.

Acta Myol. 2008 Oct;27:69-73. No abstract available.

PMID:
19364065
20.

Therapeutic effect of camostat mesilate on Duchenne muscular dystrophy in mdx mice.

Sawada H, Nagahiro K, Kikukawa Y, Ban S, Kakefuda R, Shiomi T, Yokosawa H.

Biol Pharm Bull. 2003 Jul;26(7):1025-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk